Sugi Predict

Sugi Predict / Compounds / SCHEMBL4074628

SCHEMBL4074628

SCHEMBL4074628

O=C(O)c1ccc(-c2ccccc2)[nH]c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 1.00
▸ ALDH1A1 P00352 2/20 0.66
▸ GAA P10253 1/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.66
▸ RXFP1 Q9HBX9 1/20 0.66
▸ ALOX15 P16050 1/20 0.48
▸ NOTUM Q6P988 1/20 0.47
▸ HSD17B10 Q99714 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ NAPRT Q6XQN6 1/20 0.46
▸ ALPL P05186 1/20 0.45
▸ ALPI P09923 1/20 0.45
▸ DHODH Q02127 1/20 0.45
▸ OXTR P30559 1/20 0.44
▸ USP30 Q70CQ3 1/20 0.44
▸ HTR2B P41595 1/20 0.44
▸ KDM4A O75164 1/20 0.44
▸ KDM5A P29375 1/20 0.44
▸ KDM4C Q9H3R0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4429820 0.96 KDM4E (0.93) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL17883343 0.85 KDM4E (0.74) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL11635055 0.84 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL361765 0.84 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL17844580 0.84 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL25149281 0.84 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL11111623 0.84 KDM4E (0.72) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL4070066 0.82 KDM4E (0.69) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL4431905 0.82 KDM4E (0.69) KDM4EALDH1A1GAASMN1; SMN2RXFP1
SCHEMBL11116264 0.82 KDM4E (0.69) KDM4EALDH1A1GAASMN1; SMN2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 — — US disclosed
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 — — US disclosed
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS AG (CH) 2023-06-15 — — US disclosed
WO-2023062575-A1 CYCLIC VINYL SULFONE COMPOUNDS AS WRN INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2023-04-20 — — WO disclosed
US-11466048-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA NOVARTIS AG (CH) 2022-10-11 — — US disclosed
EP-3904366-A1 END CAPPED NUCLEIC ACID MOLECULES Novartis AG (CH) 2021-11-03 — — EP disclosed
EP-3904366-A1 END CAPPED NUCLEIC ACID MOLECULES Novartis AG (CH) 2021-11-03 — — EP disclosed
EP-3762392-A1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Wellmarker Bio Co., Ltd. (KR) 2021-01-13 — — EP disclosed
CN-111848712-A End-capped nucleic acid molecules 诺华股份有限公司 2020-10-30 — — CN disclosed
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2020-06-18 — — US disclosed
WO-2006004636-A2 FUSED HETEROCYCLIC KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-01-12 — — WO disclosed
WO-2005117867-A2 MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-15 — — WO disclosed
WO-2005116028-A2 BICYCLIC HETEROCYCLES AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-08 — — WO disclosed
EP-0826671-B1 HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME MITSUBISHI PHARMA CORP (JP) 2004-12-29 — — EP disclosed
US-5948785-A USEFUL AS CHYMASE INHIBITORS AND CAN BE EFFECTIVE FOR THE PROPHYLAXIS AND TREATMENT OF VARIOUS DISEASES CAUSED BY CHYMASE, SUCH AS THOSE CAUSED BY ANGIOTENSIN II. THE GREEN CROSS CORPORATION (JP) 1999-09-07 — — US disclosed
WO-1998045266-A1 3-AMINOPYRIDINE DERIVATIVES FOR TREATMENT OF INFLAMMATORY AND MALIGNANT DISEASES FERRING B.V. (NL) 1998-10-15 — — WO disclosed
EP-0826671-A1 HETEROCYCLIC AMIDE COMPOUNDS AND MEDICINAL USE OF THE SAME THE GREEN CROSS CORPORATION (JP) 1998-03-04 — — EP disclosed
EP-0509769-B1 Heterocyclic amides having HLE inhibiting activity ZENECA LTD (GB) 1996-09-11 — — EP disclosed
US-5521179-A Heterocyclic amides ZENECA LIMITED (GB) 1996-05-28 — — US disclosed
EP-0509769-A2 Heterocyclic amides having HLE inhibiting activity ZENECA LIMITED (GB) 1992-10-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183286-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 KDM4E 1565/4885ALDH1A1 3871/4885GAA 1299/4885
US-20200190132-A1 NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA RNGTT, NSUN2, NSUN3 KDM4E 1565/4885ALDH1A1 3871/4885GAA 1299/4885
US-11466048-B2 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA RNGTT, NSUN3, NSUN2 KDM4E 1535/4885ALDH1A1 3685/4885GAA 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.